873387-82-7

Basic information

• Product Name: 3-BROMO-4-IODOBENZALDEHYDE
• Synonyms: 3-BROMO-4-IODOBENZALDEHYDE
• CAS NO: 873387-82-7
• Molecular Formula: C₇H₄BrIO
• Molecular Weight: 310.91
• Mol File: 873387-82-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-BROMO-4-IODOBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-4-IODOBENZALDEHYDE(873387-82-7)
• EPA Substance Registry System: 3-BROMO-4-IODOBENZALDEHYDE(873387-82-7)

Safety Data

• Hazardous Substances Data: 873387-82-7(Hazardous Substances Data)

Upstream product

• 1261470-90-9 C₇H₃BrClIO 
• 249647-25-4 3-bromo-4-iodobenzoic acid 
• 249647-26-5 (3-bromo-4-iodophenyl)methanol 
• 106896-49-5 methyl 4-amino-3-bromobenzoate 
• 249647-24-3 3-bromo-4-iodobenzoic acid methyl ester 
• 15164-44-0 p-(iodophenyl)carboxaldehyde 
• 101420-88-6 4-iodo-3-nitrobenzaldehyde 

Downstream Products

• 1357614-71-1 3-(3-bromo-4-iodophenyl)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazole 

Relevant articles and documents

The Discovery and Structure-Activity Evaluation of (+)-Floyocidin B and Synthetic Analogs

Tuberculosis represents one of the ten most common courses of death worldwide and the emergence of multidrug-resistant M. tuberculosis makes the discovery of novel anti-tuberculosis active structures an urgent priority. Here, we show that (+)-floyocidin B representing the first example of a novel dihydroisoquinoline class of fungus-derived natural products, displays promising antitubercular hit properties. (+)-Floyocidin B was identified by activity-guided extract screening and its structure was unambiguously determined by total synthesis. The absolute configuration was deduced from a key synthesis intermediate by single crystal X-ray diffraction analysis. A hit series was generated by the isolation of further natural congeners and the synthesis of analogs of (+)-floyocidin B. Extensive biological and physicochemical profiling of this series revealed first structure-activity relationships and set the basis for further optimization and development of this novel antitubercular scaffold.

SPIROCYCLIC ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS

The invention recites spirocyclic isoxazoline derivatives of Formula (V.1), Formula (V.2), Formula (V.1.1), and Formula (1) stereoisomers thereof, veterinarily acceptable salts thereof, compositions thereof, processes for making, and their use as a parasi

ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS

This invention recites isoxazoline substituted azetidine derivatives of Formula (1) stereoisomers thereof, veterinarily acceptable salts thereof, compositions thereof, and their use as a parasiticide in mammals and birds. R1a, R1b, R1c, R2, R3, R4, R6, and n are as described herein.